A personalized blood test measuring circulating tumor DNA (ctDNA) can identify colorectal cancer patients who benefit most from adjuvant chemotherapy after liver metastasis surgery. According to the Phase II GALAXY study presented at the ESMO Gastrointestinal Cancers Congress 2026, patients with detectable ctDNA after surgery saw overall survival rates of 65% with chemotherapy, compared to … Read more
A blood test detecting circulating tumour DNA (ctDNA) after surgery can identify colorectal cancer patients most likely to benefit from adjuvant chemotherapy, according to research presented at the 2026 ESMO Gastrointestinal Cancers Congress. The Phase II GALAXY study, led by researchers from Hyogo Medical University and collaborators including the University of Oxford, found that patients … Read more
The U.S. Food and Drug Administration approved zenocutuzumab as a second-line therapy for NRG1-positive cholangiocarcinoma on May 8. According to results from the eNRGy phase 2 clinical trial published in the Journal of Clinical Oncology, the drug more than doubled the median progression-free survival to 9.2 months, compared to the approximately four months typically seen … Read more
Researchers at The University of Texas MD Anderson Cancer Center have mapped the spatial architecture of muscle-invasive bladder cancer, identifying how tumor cell states and immune environments interact within specific regions of a tumor. Published in Cancer Discovery, the study reveals that bladder cancer is not a uniform disease, but a complex landscape where luminal … Read more
New Medicaid work requirements mandated by the federal government are set to take effect next year, creating significant uncertainty for millions of enrollees who rely on the program for life-saving medical care. Under new guidance from the Centers for Medicare and Medicaid Services (CMS), participants will be required to document 80 hours of monthly work, … Read more
A genomic test can identify many breast cancer patients who can safely forgo chemotherapy without increasing their risk of recurrence, according to results from the international OPTIMA trial presented at the 2026 American Society of Clinical Oncology meeting. Researchers found that patients aged 40 and over with hormone-sensitive tumors and a low Prosigna test score … Read more
Beyond the Diagnosis: The New Frontier of Survivorship For millions, the final round of chemotherapy is hailed as a victory. But as medical advancements continue to increase survival rates, a new, complex reality is emerging: the “second diagnosis.” This isn’t a medical recurrence, but a social and economic one—the struggle to reintegrate into a workforce … Read more
A cancer diagnosis at any age is life-altering, but for young women, it often triggers a secondary, urgent crisis: the sudden collision of medical necessity and reproductive autonomy. When time is compressed into a 30-minute window, the decision to undergo fertility preservation—often while grappling with the physical and emotional toll of surgery and impending treatment—is … Read more
A Dual-Action Future: Could Anemia Drugs Transform Cancer Treatment? For cancer patients, managing the disease often feels like a balancing act. Between the aggressive nature of tumors and the debilitating side effects of chemotherapy, patients frequently battle a secondary, yet equally taxing, condition: anemia. Now, groundbreaking research suggests that a class of medications already used … Read more
Integrative Oncology: Why Gentle Yoga is Changing Survivorship For millions of people navigating life after a cancer diagnosis, the transition from active treatment to survivorship can be physically and emotionally taxing. Recent clinical research from the Wilmot Cancer Institute highlights a promising, non-drug approach to managing the lingering side effects of surgery and chemotherapy: gentle, … Read more